206 related articles for article (PubMed ID: 33082514)
1. The deubiquitinase JOSD2 is a positive regulator of glucose metabolism.
Krassikova L; Zhang B; Nagarajan D; Queiroz AL; Kacal M; Samakidis E; Vakifahmetoglu-Norberg H; Norberg E
Cell Death Differ; 2021 Mar; 28(3):1091-1109. PubMed ID: 33082514
[TBL] [Abstract][Full Text] [Related]
2. PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Zhang B; Zheng A; Hydbring P; Ambroise G; Ouchida AT; Goiny M; Vakifahmetoglu-Norberg H; Norberg E
Cell Rep; 2017 Jun; 19(11):2289-2303. PubMed ID: 28614715
[TBL] [Abstract][Full Text] [Related]
3. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
4. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.
Yuan T; Zeng C; Liu J; Zhao C; Ge F; Li Y; Qian M; Du J; Wang W; Li Y; Liu Y; Dai X; Zhou J; Chen X; Ma S; Zhu H; He Q; Yang B
Signal Transduct Target Ther; 2024 Jan; 9(1):11. PubMed ID: 38177135
[TBL] [Abstract][Full Text] [Related]
5. Association of C-terminal region of phosphoglycerate mutase with glycolytic complex regulates energy production in cancer cells.
Kowalski W; Nocon D; Gamian A; Kołodziej J; Rakus D
J Cell Physiol; 2012 Jun; 227(6):2613-21. PubMed ID: 22367961
[TBL] [Abstract][Full Text] [Related]
6. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
[TBL] [Abstract][Full Text] [Related]
7. NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells.
Zeng C; Wu Q; Wang J; Yao B; Ma L; Yang Z; Li J; Liu B
Free Radic Biol Med; 2016 Dec; 101():236-248. PubMed ID: 27989748
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis.
Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G
Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748
[No Abstract] [Full Text] [Related]
9. Ad-apoptin inhibits glycolysis, migration and invasion in lung cancer cells targeting AMPK/mTOR signaling pathway.
Song G; Fang J; Shang C; Li Y; Zhu Y; Xiu Z; Sun L; Jin N; Li X
Exp Cell Res; 2021 Dec; 409(2):112926. PubMed ID: 34793774
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.
Chang L; Fang S; Chen Y; Yang Z; Yuan Y; Zhang J; Ye L; Gu W
Lipids Health Dis; 2019 May; 18(1):118. PubMed ID: 31122252
[TBL] [Abstract][Full Text] [Related]
11. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Liu J; Zhang C; Wu H; Sun XX; Li Y; Huang S; Yue X; Lu SE; Shen Z; Su X; White E; Haffty BG; Hu W; Feng Z
J Clin Invest; 2020 Jun; 130(6):3253-3269. PubMed ID: 32478681
[TBL] [Abstract][Full Text] [Related]
12. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.
Ge F; Liu X; Zhang H; Yuan T; Zhu H; Yang B; He Q
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):533-543. PubMed ID: 37899394
[TBL] [Abstract][Full Text] [Related]
14. Glucose metabolism provide distinct prosurvival benefits to non-small cell lung carcinomas.
Wu R; Galan-Acosta L; Norberg E
Biochem Biophys Res Commun; 2015 May; 460(3):572-7. PubMed ID: 25819414
[TBL] [Abstract][Full Text] [Related]
15. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Chesney J; Clark J; Lanceta L; Trent JO; Telang S
Oncotarget; 2015 Jul; 6(20):18001-11. PubMed ID: 26221874
[TBL] [Abstract][Full Text] [Related]
16. JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis.
Seki T; Gong L; Williams AJ; Sakai N; Todi SV; Paulson HL
J Biol Chem; 2013 Jun; 288(24):17145-55. PubMed ID: 23625928
[TBL] [Abstract][Full Text] [Related]
17. SOX9-mediated UGT8 expression promotes glycolysis and maintains the malignancy of non-small cell lung cancer.
Ji J; Xie M; Qian Q; Xu Y; Shi W; Chen Z; Ren D; Liu W; He X; Lv M; Ma J; Liu W; Li A; Liu B
Biochem Biophys Res Commun; 2022 Jan; 587():139-145. PubMed ID: 34872002
[TBL] [Abstract][Full Text] [Related]
18. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Qian M; Yan F; Wang W; Du J; Yuan T; Wu R; Zhao C; Wang J; Lu J; Zhang B; Lin N; Dong X; Dai X; Dong X; Yang B; Zhu H; He Q
Acta Pharm Sin B; 2021 Dec; 11(12):4008-4019. PubMed ID: 35024322
[TBL] [Abstract][Full Text] [Related]
19. Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism.
Zhao JG; Ren KM; Tang J
Tumour Biol; 2014 Dec; 35(12):12305-15. PubMed ID: 25260882
[TBL] [Abstract][Full Text] [Related]
20. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.
Wei L; Dai Q; Zhou Y; Zou M; Li Z; Lu N; Guo Q
Biochim Biophys Acta; 2013 Jun; 1830(6):3835-45. PubMed ID: 23500080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
